Search

Your search keyword '"Döcke, W D"' showing total 199 results
Start Over Author "Döcke, W D"
199 results on '"Döcke, W D"'

13. The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction

Author

Witte-Händel, E. Wolk, K. Tsaousi, A. Irmer, M.L. Mößner, R. Shomroni, O. Lingner, T. Witte, K. Kunkel, D. Salinas, G. Jodl, S. Schmidt, N. Sterry, W. Volk, H.-D. Giamarellos-Bourboulis, E.J. Pokrywka, A. Döcke, W.-D. Schneider-Burrus, S. Sabat, R.

Abstract

Hidradenitis suppurativa (HS)(also designated acne inversa)is a chronic inflammatory disease characterized by painful purulent skin lesions and progressive destruction of skin architecture. Despite the high burden for the patients, pathogenetic pathways underlying HS alterations remain obscure. When we examined the HS cytokine pattern, IL-1β turned out to be a highly prominent cytokine, overexpressed even compared with psoriatic lesions. Analyses of IL-1β–induced transcriptome in various cell types showed overlapping profiles, with upregulations of molecules causing immune cell infiltration and extracellular matrix degradation, and of specific cytokines including IL-6, IL-32, and IL-36. Matching cellular IL-1 receptor levels, dermal fibroblasts showed both the strongest and broadest IL-1β response, which was not clearly shared or strengthened by other cytokines. The IL-1β signature was specifically present in HS lesions and could be reversed by application of IL-1 receptor antagonist. Search for blood parameters associated with IL-1β pathway activity in HS identified serum amyloid A, which was synergistically induced by IL-1β and IL-6 in hepatocytes. Consequently, strongly elevated blood serum amyloid A levels in HS correlated positively with the extent of inflammatory skin alterations. In summary, the IL-1β pathway represents a pathogenetic cascade, whose activity may be therapeutically targeted and monitored by blood SAA levels. © 2018 The Authors

Published
2019

50. Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies.

Author

Sabat, Robert, Höflich, Conny, Döcke, Wolf-Dietrich, Oppert, Michael, Kern, Florian, Windric, Bettina, Rosenberger, Christian, Kaden, Jürgen, Volk, Hans-Dieter, Reinke, Petra, Sabat, R, Höflich, C, Döcke, W D, Oppert, M, Kern, F, Windrich, B, Rosenberger, C, Kaden, J, Volk, H D, and Reinke, P

Subjects
THERAPEUTICS, CRITICAL care medicine, MONOCLONAL antibodies, TUMOR necrosis factors, GROWTH factors, INTERNAL medicine, IMMUNOSUPPRESSIVE agents, ANTILYMPHOCYTIC serum, MUROMONAB-CD3, CALCITONIN, KIDNEY transplantation, NEUROPEPTIDES, PROTEIN precursors, T cells, RETROSPECTIVE studies
Abstract

Objective: To determine the value of procalcitonin (PCT) monitoring in transplant patients receiving pan-T-cell antibody therapy.Design: Retrospective clinical study.Setting: A collaborative study between the Institute of Medical Immunology, the Department of Nephrology and Internal Intensive Care, both Charite, Humboldt University Berlin, and the Department of Laboratory Medicine, Friedrichshain Hospital, Berlin, Germany.Patients and Interventions: Thirty-one patients were included in the study: 8 kidney transplant patients with acute rejection episodes, 5 receiving OKT3 monoclonal antibody therapy, 3 receiving steroid bolus therapy; 21 patients undergoing renal transplantation, 11 receiving ATG perioperatively, 10 without ATG administration; 2 patients undergoing renal transplantation and receiving anti-IL-2R mAb.Measurements and Results: Procalcitonin (PCT) and tumor necrosis factor (TNF) alpha plasma levels were measured in infection-free transplant patients treated with the pan-T-cell antibodies ATG or OKT3. We found PCT plasma concentrations up to 600 ng/ml (reference < 0.5 ng/ ml), which are comparable to those seen in severe sepsis. Increases in TNF-alpha plasma levels preceded the rises in PCT. After peaking on day 1 of therapy the PCT plasma concentrations returned to normal values independently of further antibody administration. In contrast, steroid bolus therapy or anti-interleukin 2 receptor mAb administration did not increase plasma PCT or TNF-alpha levels.Conclusions: PCT monitoring for evaluating infectious complications in kidney transplant patients must be very careful during pan-T-cell antibody therapy. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results